# Regulatory Writing Portfolio â€“ Rinvoq (Upadacitinib)

This repository contains sample **Common Technical Document (CTD) Module 1-5 sections** prepared as part of a regulatory writing portfolio project.  
The drug selected is **Upadacitinib (RinvoqÂ®)**, a selective JAK1 inhibitor approved for multiple autoimmune conditions.

## ğŸ“‚ Contents
- **ectd-rinvoq.pdf** â€“ Combined document containing the drafted CTD sections.
- **2.3 Quality Overall Summary (QOS)** â€“ Summary of Chemistry, Manufacturing, and Controls (CMC).
- **2.5 Clinical Overview** â€“ High-level summary of clinical development, safety, and efficacy.
- **2.7 Clinical Summaries** â€“ Detailed summaries of clinical pharmacology, efficacy, and safety data.

## ğŸ§¾ Purpose
- Demonstrate ability to author and compile regulatory documents in compliance with **ICH M4 CTD format**.
- Showcase clarity, structure, and scientific writing skills relevant to **regulatory submissions**.
- Provide a portfolio sample for prospective employers and collaborators.

## âš ï¸ Disclaimer
This project is for **educational and portfolio purposes only**.  
It is a **mock regulatory submission** based on publicly available information and academic knowledge.  
It does not represent official AbbVie documents or confidential regulatory filings.

---

ğŸ‘©â€ğŸ’» Author: Sakshi Vashisth  
ğŸ“Œ Created as part of a **Regulatory Writing Portfolio Project (2025)**
